KRAS testing

The recent study highlights strengths and weaknesses of numerous platforms and may help end users choose the best assay for their circumstances.

The test detects 21 relevant mutations in the KRAS oncogene including mutations in exons 2, 3, and 4. 

The test helps to identify metastatic colorectal cancer patients for whom treatment with Erbitux (cetuximab) or Vectibix (panitumumab) may be effective because their tumors carry no KRAS mutations.

The customizable PCR plates may also be less expensive than the FDA-approved Therascreen kits.

Transgenomic announced this week that it has signed an agreement with Amgen to develop an IVD test to identify NRAS and KRAS mutated patients with advanced colorectal cancer using its RAScan kits.

Momentum from the 2011 launch of two highly anticipated personalized medicine cancer treatments — Pfizer's Xalkori and Roche's Zelboraf — continued to spur pharmaceutical companies and test makers to engage in drug and diagnostic codevelopment collaborations throughout 2012.

After a survey of UK oncologists revealed that access hurdles and high costs associated with biomarker testing are limiting their ability to prescribe personalized treatments, Merck Serono has issued a "call to action" for the government and pharmaceutical industry to work togeth

Anagnostics said this week that it has tapped fellow Austrian firm Vela Laboratories to be its first service partner. Vienna-based Vela will now offer its pharmaceutical and biotech clients the ability to use Anagnostics' cylindrical HybCell microarray platform.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.